227. オスラー病 Osler disease Clinical trials / Disease details


臨床試験数 : 54 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03954782
(ClinicalTrials.gov)
June 22, 202015/5/2019Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II StudyTelangiectasia, Hereditary Hemorrhagic;Rendu Osler DiseaseDrug: Nintedanib 150 mg and 100 mg soft capsules;Drug: Oral treatment of placebo soft capsuleHospices Civils de LyonNULLRecruiting18 YearsN/AAll60Phase 2France
2EUCTR2019-002593-31-FR
(EUCTR)
05/11/201905/09/2019Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREEfficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseA national, randomized, multicenter phase II studyEPICURE Hereditary Hemorrhagic Telangiectasia
MedDRA version: 20.1;Level: LLT;Classification code 10019887;Term: Hereditary hemorrhagic telangiectasia;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: OFEV
Product Name: nintédanib
Other descriptive name: NINTEDANIB
Hospices Civils de LyonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2France